Olaparib in Patients With HRD Malignant Mesothelioma

NCT04515836 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Mesothelioma
Homologous Recombination Deficiency

Interventions

DRUG: Olaparib

Sponsor

University of Chicago

Collaborators

[object Object]